Hospital Quironsalud Zaragoza
- Address
- lock Available on a paid plan
Congenital, Hereditary, and Neonatal Diseases
The research program at Hospital Quironsalud Zaragoza focuses on rare genetic disorders, evaluating the safety and long‑term efficacy of enzyme replacement and substrate reduction strategies for conditions such as Fabry disease and Gaucher disease.
- Enzyme replacement therapy evaluation
- Substrate reduction therapy safety
- Pediatric dosing strategies
- Long‑term disease monitoring
Multidisciplinary clinicians collaborate to improve outcomes for patients with inherited metabolic diseases, offering access to innovative therapies within a dedicated haematology department.
Hemic and Lymphatic Diseases
In the haematology unit, investigators explore new treatment options for blood‑cancer and myeloproliferative disorders, including Chronic Myeloid Leukemia, Myelofibrosis and Polycythemia Vera. Trials aim to enhance disease control, reduce symptom burden, and improve survival.
- Targeted kinase inhibition
- Combination with JAK inhibitors
- Spleen volume reduction strategies
- Symptom burden improvement
With eight investigators overseeing fourteen active studies, the site provides patients access to cutting‑edge therapies while generating valuable safety and efficacy data.
Neoplasms
Oncology research at the centre evaluates novel antibody‑drug conjugates and endocrine combinations for HR‑positive, HER2‑low advanced breast cancer, seeking to extend progression‑free survival and offer new options for patients with limited treatment choices.
- Antibody‑drug conjugate efficacy
- Comparative endocrine therapy
- Biomarker‑driven patient selection
- Survival outcome analysis
The collaborative effort integrates haematology expertise with oncology specialists, fostering a comprehensive approach to cancer care at the Zaragoza hospital.
Nutritional and Metabolic Diseases
The department conducts trials to address iron deficiency, comparing oral formulations such as Sucrosomial® Iron and Ferric Maltol for rapid hemoglobin normalization and improved tolerability in affected individuals.
- Oral iron absorption studies
- Hemoglobin normalization outcomes
- Tolerability comparison
- Patient‑reported quality‑of‑life measures
By integrating metabolic research within its haematology services, Hospital Quironsalud Zaragoza offers patients evidence‑based options to manage nutritional disorders effectively.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Kartos Therapeutics Inc.1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Kartos Therapeutics Inc.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Quironsalud Zaragoza
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study of Imetelstat Versus Best Available Therapy in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK-Inhibitors | Geron Corp. | Phase III | Not Recruiting | Apr 2021 | — |
IMP list
lock Showing 1 of 39 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ruxolitinib | 3 | Unknown | 2022-04-22 | 2024-10-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.